Payment overview · 2025
General Payments
$497.82
27 reported records · 14 companies
Healthcare provider profile · identity verified
Laura T Logan, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · JACKSONVILLE BEACH, FL · NPI 1497098586
Verified facts
What the public records show
CMS Open Payments records show Laura T Logan, APRN received $497.82 in general payments during 2025 across 27 reported records.
Amgen Inc. accounted for 18.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Paxlovid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $90.97 | 18.3% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $76.59 | 15.4% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $56.04 | 11.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $42.35 | 8.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.78 | 7.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $35.16 | 7.1% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $25.84 | 5.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.09 | 4.4% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $20.43 | 4.1% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $20.20 | 4.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.59 | 3.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.47 | 3.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.24 | 3.5% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $17.07 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $497.82 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $90.97 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $90.97 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $76.59 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $56.04 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $42.35 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $42.35 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $25.84 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.09 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $20.43 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $20.20 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $19.59 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.51 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.51 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.33 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $17.47 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 36 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
62 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
36 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 366 | 116 |
| Levothyroxine Sodium | Levothyroxine Sodium | 342 | 99 |
| Amlodipine Besylate | Amlodipine Besylate | 253 | 79 |
| Losartan Potassium | Losartan Potassium | 216 | 66 |
| Atorvastatin Calcium | Atorvastatin Calcium | 181 | 56 |
| Alprazolam | Alprazolam | 170 | 64 |
| Sertraline Hcl | Sertraline Hcl | 130 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 128 | 42 |
| Azithromycin | Azithromycin | 127 | 113 |
| Metoprolol Succinate | Metoprolol Succinate | 120 | 35 |
| Lisinopril | Lisinopril | 116 | 38 |
| Irbesartan | Irbesartan | 92 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 90 | 77 |
| Montelukast Sodium | Montelukast Sodium | 83 | 27 |
| Omeprazole | Omeprazole | 78 | 32 |
| Valsartan | Valsartan | 78 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 77 | 39 |
| Metformin Hcl Er | Metformin Hcl | 70 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 23 |
| Cefdinir | Cefdinir | 63 | 56 |
| Synthroid | Levothyroxine Sodium | 62 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | 29 |
| Gabapentin | Gabapentin | 60 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 30 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 55 | 50 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 54 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 53 | 16 |
| Ezetimibe | Ezetimibe | 51 | 16 |
| Metformin Hcl | Metformin Hcl | 48 | 15 |
| Alendronate Sodium | Alendronate Sodium | 47 | 24 |
| Simvastatin | Simvastatin | 47 | 12 |
| Methylprednisolone | Methylprednisolone | 46 | 44 |
| Trazodone Hcl | Trazodone Hcl | 46 | 17 |
| Valacyclovir | Valacyclovir Hcl | 46 | 30 |
| Allopurinol | Allopurinol | 42 | 12 |
| Bupropion Xl | Bupropion Hcl | 38 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 36 | 36 |
| Fluconazole | Fluconazole | 34 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 33 | 13 |
| Temazepam | Temazepam | 33 | 15 |
| Carvedilol | Carvedilol | 30 | suppressed |
| Mupirocin | Mupirocin | 30 | 26 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 28 |
| Prednisone | Prednisone | 28 | 20 |
| Meloxicam | Meloxicam | 27 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 26 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 23 |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | 12 |
| Folic Acid | Folic Acid | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | 11 |
| Lorazepam | Lorazepam | 21 | 12 |
| Clonazepam | Clonazepam | 20 | suppressed |
| Potassium Chloride | Potassium Chloride | 19 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 16 |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 15 |
| Famotidine | Famotidine | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | 12 |
| Atenolol | Atenolol | 14 | suppressed |
| Eliquis | Apixaban | 14 | suppressed |
| Furosemide | Furosemide | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | 12 |
| Nystatin | Nystatin | 14 | 12 |
| Spironolactone | Spironolactone | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 13 |
| Trulicity | Dulaglutide | 13 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $497.82 · 27 records | Amgen Inc. | AIRSUPRA, Cologuard Collection Kit, FARXIGA, GEMTESA, General - Pain Management, Kerendia, LEQVIO, MOUNJARO, OTEZLA, Ozempic, PAXLOVID, QUTENZA, REPATHA, Rybelsus, UBRELVY, Veozah, Wegovy, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error